Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
LaNova Australia Pty Limited
This study has two arms, and each arm has a dose escalation phase and a dose expansion phase. In Arm A, participants will receive LM-108 as monotherapy, administered intravenously. In Am B, participants will receive LM-108 in combination with an Anti-PD-1 Antibody, both administered intravenously.